Please assess the completion status of the following clinical trial:

Trial Title: Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \<= 60 and undergoing allogeneic HSCT~* Life expectancy \> 8 weeks~* Scheduled for treatment with a conditioning regimen intended to be myeloablative~* Female subjects of child-bearing age must have a negative urine pregnancy test. Sexually active male and female subjects of reproductive age must be using a form of contraception considered effective and medically acceptable by the Investigator.~Exclusion Criteria:~* Cumulative lifetime exposure of \> 300 mg/M2 of anthracycline (expressed as doxorubicin equivalent dose) or receipt of anthracycline within 180 days prior to initiating conditioning for HSCT~* Active infection~* Prophylactic antibacterial antibiotics.~* Positive for HIV, HTLV-I, or HTLV-II~* Any prior stem cell transplant~* Prior history of CHF~* Cord blood is the source of a subject's transplanted cells.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Opebacan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).